To examine market access timelines and HTA assessments for medicines approved under exceptional circumstances by the European Medicines Agency (EMA) between January 2009 and December 2017
BACKGROUND
• For certain categories of medicinal products, in order to meet unmet medical needs of patients and in the interest of public health, EMA may grant a marketing authorisation in absence of comprehensive data under exceptional circumstances • Reasons that medicinal products that would qualify without comprehensive data on the efficacy and safety could be because : -Indication is encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or -In the present state of scientific knowledge, comprehensive information cannot be provided, or -It would be contrary to generally accepted principles of medical ethics to collect such information.
• Unlike conditional marketing authorisation, where marketing approval is granted in the likelihood that the sponsor will provide such data within an agreed timeframe, authorisation under exceptional circumstances can be granted when comprehensive data cannot be obtained even after authorisation -Authorisation initially valid for 5 years (renewable), but the status of fulfilment of the specific obligations and the impact of the specific obligations' data on the benefit / risk balance is to be reassessed annually -This authorisation route normally does not lead to a standard marketing authorisation Table 3 • Time to market for drugs approved under exceptional circumstances is substantially longer compared to national averages for all drugs across the EU5 countries (except Germany where timelines are similar)-see Table 3 • HTA assessments published so far for 11 drugs in France (79%), but only 7 in Germany (50%) and 6 in the UK (43%) -In Germany reasons for lack of G-BA assessments include known active substance, insignificant costs to sickness funds, blood products and in one case approval prior to AMNOG implementation -In the UK, guidance for 6 drugs is in development by NICE/NHS England (2 are being reviewed via Highly Specialised Technology-HST process) • In France and Germany, level of incremental benefit assigned upon reviewing available evidence package tends to be low -Of the 11 drugs reviewed in France 2 drugs have no ASMR assigned based on insufficient SMR 7 drugs assigned ASMR IV/V Only 2 drugs have ASMR of I or II -Germany: Only 7 drugs (50%) have G-BA assessment 5 are assigned non quantifiable added benefit rating (71%) 1 assigned no added benefit (no orphan designation in the approved indication) and Only 1 has minor added benefit
CONCLUSIONS
• It is important to recognize that, while approval under exceptional circumstances may be a path to regulatory approval, it could be challenging from a market access perspective -In France and Spain, less than 50% of these drugs have completed P&R negotiations in the last nine years -Timelines for access are substantially longer especially in Italy and Spain In Italy, this could be due to the high proportion of repurposed molecules that are not viewed favourably by authorities -HTA in Germany is often negative with potential impact on price negotiations, particularly when a drug does not have orphan designation -Lower percentage of drugs approved under exceptional circumstances are on the UK market with timelines for guidance development being long Approximately 50% of the drugs have a NICE guidance in development Final decisions result in restricted access with negotiated patient access schemes or managed access schemes/commercial agreements • Closer interaction between regulators, HTA bodies and manufacturers is required to ensure that regulatory approval pathway can translate into a route to patient access • National agencies can make very different decisions upon reviewing the same clinical data -Two drugs with strong ASMR ratings in France (asfotase alfa and cholic acid) assigned non-quantifiable added benefit rating in Germany • In the UK, positive recommendations/guidance are almost always based on a negotiated PAS or MAA -England: Except for one drug that is not recommended, all others reviewed are recommended for restricted use as per criteria, PAS or managed access scheme -Scotland: Only 6 drugs reviewed by the SMC, of which 4 are not recommended and 2 are accepted with PAS
